My career goal is to improve the lives of men with urologic malignancies by providing accessible patient-centered clinical care, developing novel experimental therapeutic approaches, and creating an environment that trains the next generation of leaders in prostate cancer clinical research. In order to accomplish these goals, I completed by MD PhD in in the laboratory of Craig Thompson at the University of Pennsylvania and a clinical research postdoctoral fellowship under the mentorship of Charles Sawyers and Howard Scher, leaders in basic and translational prostate cancer research at MSKCC. I am currently the Director of Genitourinary Medical Oncology at the Perlmutter Cancer Center at NYU Langone Health, where my research focuses on early phase clinical trials of first-in-class therapeutics for advanced prostate cancer, bladder, and kidney cancer. My research focuses on clinical development of first-in-class therapeutics for advanced prostate cancer, development of novel immune intact preclinical platforms for drug target validation, and the study of novel genomic biomarkers. My prior work led to the identification of DKK1 as a therapeutic target for aggressive variant metastatic prostate cancer. Based on this work, I lead an investigator-initiated clinical trial testing the DKK1 inhibitor antibody, DKN01 for the treatment of metastatic castration-resistant prostate cancer. I have also developed a clinical trials program focused on novel immunomodulatory and targeted agents as well as on innovative strategies to improve somatic and germline genetic testing.